Now available: WFH Humanitarian Aid Program Impact Report 2018

A new report—called the “WFH Humanitarian Aid Program: Impact Report 2018”—has just been released. The document shows the impact that the WFH Humanitarian Aid Program has had on the global bleeding disorders community.

The lack of access to care and treatment for people affected with a bleeding disorder in developing countries is an urgent and important public health challenge. The WFH Humanitarian Aid Program is leading the effort to change this lack of access in developing countries by providing consistent and predictable access to Treatment for All.

The WFH Humanitarian Aid Program has drastically accelerated treatment donations over the last five years. Now, more people than ever in the bleeding disorders community have hope that they can have a better quality of life. Last year alone, the WFH Humanitarian Aid Program was able to facilitate significant support of patients everywhere.

Through collaborations—with governments, with corporate partners, and with local organizations—the program has been able to support communities and give them tools and resources to support their patients. The report contains many case studies which are both inspirational and informative. They show how the WFH Humanitarian Aid Program was able to have an impact in communities.

None of this would be possible without the generous support of our corporate partners. Their multi-year commitments to supply predictable donated treatment products, and their generous financial support ensure that the WFH is able to reach its goal of bringing sustainable change to those living with little or no access to treatment.

To read the full report “WFH Humanitarian Aid Program: Impact Report 2018”, please click here.

CONTRIBUTORS TO THE WFH HUMANITARIAN AID PROGRAM

The visionary contribution from Sanofi Genzyme and Sobi to the WFH Humanitarian Aid Program translates into 500 million IUs over five years (2015-2020). Sanofi Genzyme and Sobi also make ongoing substantial financial contributions to support the logistics of product delivery and training of providers and patients in humanitarian aid countries. Furthermore, the eight-year commitment (2014-2021) from Grifols totaling 200 million IUs, along with a ten-year commitment (2009-2018) from CSL Behring for a total of 22 million IUs, and the three-year agreement (2017-2019) with GC Pharma for 6 million IUs, allows for a more predictable and sustainable flow of humanitarian aid donations to the global community.

Charitable solicitations for the common purposes of WFH and WFH USA within the U.S. are conducted through WFH USA, a 501(c)3 affiliated entity.